“She was given 1-3 months.”
I’m 99% sure this is incorrect and that during one interview he stated something along the lines of, “few months to 9 months.” Now, was that timeline given by a doctor just before the leronlimab injection or 6 months prior? Who knows. I wrote in my notes about NP’s MIL that she had 3-9 months and that was written in NOV or DEC. Unfortunately I don’t write which interview it was from and between the proactive videos, podcasts and radio interviews, I don’t have the time to go back and find it. Regardless, my point is that it appears CYDY will need more data on leronlimab and mTNBC before we get approval and that may stretch into the end of 2020 or beginning of 2021. I hope for it to be sooner for patients sake, and for my pocket books, but enrollment takes time and so does the FDA process.
And I personally don’t care about NK. Sure, I hope the drug works, but I simply am using them as a potential reference for the process and timeline for mTNBC. Yes, leronlimab has a longer safety history, etc., but that didn’t help much when the FDA delayed our combo BLA by a year to ask for even more data. The good is that NK’s SP jumped nearly 400% (maybe more) after mTNBC data in February (9 patients, 13 months). I didn’t check their market cap or float, but it indicates that Corning good results could equal big $ for CYDY but the company needs to get on the big boards to do so.
And I’ve got to point out that you, misu and others “IMO” and quotes about how you’re comments are not investment advice are hilarious. We now have posters who put “IMO” at the end of every sentence or phrase because they’re afraid of the SEC or FBI raiding their house. It’s comically annoying. Of course, this is all IMO.
I’m 99% sure this is incorrect and that during one interview he stated something along the lines of, “few months to 9 months.” Now, was that timeline given by a doctor just before the leronlimab injection or 6 months prior? Who knows. I wrote in my notes about NP’s MIL that she had 3-9 months and that was written in NOV or DEC. Unfortunately I don’t write which interview it was from and between the proactive videos, podcasts and radio interviews, I don’t have the time to go back and find it. Regardless, my point is that it appears CYDY will need more data on leronlimab and mTNBC before we get approval and that may stretch into the end of 2020 or beginning of 2021. I hope for it to be sooner for patients sake, and for my pocket books, but enrollment takes time and so does the FDA process.
And I personally don’t care about NK. Sure, I hope the drug works, but I simply am using them as a potential reference for the process and timeline for mTNBC. Yes, leronlimab has a longer safety history, etc., but that didn’t help much when the FDA delayed our combo BLA by a year to ask for even more data. The good is that NK’s SP jumped nearly 400% (maybe more) after mTNBC data in February (9 patients, 13 months). I didn’t check their market cap or float, but it indicates that Corning good results could equal big $ for CYDY but the company needs to get on the big boards to do so.
And I’ve got to point out that you, misu and others “IMO” and quotes about how you’re comments are not investment advice are hilarious. We now have posters who put “IMO” at the end of every sentence or phrase because they’re afraid of the SEC or FBI raiding their house. It’s comically annoying. Of course, this is all IMO.
1
2
